Breaking News Instant updates and real-time market news.

MYGN

Myriad Genetics

$23.66

0.2 (0.85%)

, NVTA

Invitae

$9.45

-0.06 (-0.63%)

10:25
07/31/17
07/31
10:25
07/31/17
10:25

William Blair healthcare analyst holds an analyst/industry conference call

Healthcare--Diagnostic Services/Life Sciences Analyst, Amanda Murphy, along with Yuriy Shevchenko, an independent consultant who has worked for Ambry Labs, GeneDx and the Icahn School of Medicine at Mt. Sinai, discuss genetic testing on an Analyst/Industry conference call to be held on July 31 at 11 am.

MYGN

Myriad Genetics

$23.66

0.2 (0.85%)

NVTA

Invitae

$9.45

-0.06 (-0.63%)

LH

LabCorp

$159.97

-0.1 (-0.06%)

DGX

Quest Diagnostics

$109.36

-0.15 (-0.14%)

ILMN

Illumina

$174.92

0.59 (0.34%)

PACB

Pacific Biosciences

$3.23

-0.02 (-0.62%)

QGEN

QIAGEN

$33.16

-1.11 (-3.24%)

  • 31

    Jul

  • 31

    Jul

  • 01

    Aug

  • 02

    Aug

  • 02

    Aug

  • 07

    Aug

  • 08

    Aug

  • 21

    Aug

MYGN Myriad Genetics
$23.66

0.2 (0.85%)

06/29/17
JPMS
06/29/17
NO CHANGE
Target $16
JPMS
Underweight
JPMorgan keeps Underweight rating, $16 target on Myriad Genetics
With the shares up 30% over the past month, JPMorgan analyst Tycho Peterson maintains an Underweight rating on Myriad Genetics with a $16 price target. While the company's pipeline "intriguing," it is not enough to offset a continued decline in the core hereditary cancer business, Peterson tells investors in a research note. He believes near-term catalysts could drive the stock "meaningfully higher or lower," and highlights the FY18 guidance in the Q4 earnings report as being the most significant upcoming event.
04/05/17
04/05/17
NO CHANGE

Myriad Genetics publishes pivotal studies for myPath melanoma test
Myriad Genetics has published the third clinical validation study and second clinical utility study for its myPath Melanoma test, which completes the reimbursement dossier for the product. The company will submit the reimbursement dossier to Medicare and private insurers three months earlier than expected. myPath Melanoma is an objective genetic test that measures 23 genes to help differentiate malignant melanoma from benign lesions. The third clinical validation was published in the journal Cancer Epidemiology, Biomarkers & Prevention. The study assessed the performance of the myPath Melanoma test in an independent cohort of 182 patients with melanocytic lesions against clinically proven outcomes. The results showed that the myPath Melanoma test had an overall diagnostic accuracy of 95% to effectively differentiate melanoma from benign lesions. The second clinical utility study was designed to evaluate changes in real world patient management based upon the myPath Melanoma test result. Results showed a 71% change in patient management from pre-test recommendations and an 81% reduction in biopsy site re-excisions for patients with a benign test result.
03/28/17
DBAB
03/28/17
NO CHANGE
Target $15
DBAB
Sell
Zejula label removes upside catalyst for Myriad, says Deutsche Bank
Deutsche Bank analyst Dan Leonard says FDA approval of Tesaro's (TSRO) Zejula, with a "broad rather than biomarker-limited label," removes one potential upside catalyst for Myriad Genetics (MYGN). While some investors are surprised by the broad label, many had already discounted the possibility of a label that limited usage to biomarker positive patients, which would have benefited test-supplier Myriad, Leonard tells investors in a research note. The analyst keeps a Sell rating on Myriad with a $15 price target.
03/13/17
SPHN
03/13/17
UPGRADE
SPHN
Overweight
Myriad Genetics upgraded to Overweight from Equal Weight at Stephens
NVTA Invitae
$9.45

-0.06 (-0.63%)

11/10/16
LEER
11/10/16
INITIATION
Target $12
LEER
Outperform
Invitae resumed with an Outperform at Leerink
Leerink analyst Puneet Souda resumed coverage of Invitae with an Outperform rating and $12 price target.
02/14/17
BNCH
02/14/17
UPGRADE
Target $11
BNCH
Buy
Invitae upgraded to Buy from Hold at Benchmark
Benchmark analyst Raymond Myers upgraded Invitae to Buy citing the company's "strong" Q4 results and "realistic" guidance for 2017. Favorable reimbursement with Medicare and a host managed care payors position Invitae to move towards profitability over the next three years, Myers tells investors in a post-earnings research note. He raised his price target for the shares to $11 from $8.50.
04/03/17
BNCH
04/03/17
NO CHANGE
Target $16
BNCH
Buy
Invitae price target raised to $16 from $11 at Benchmark
Benchmark analyst Raymond Myers noted that Invitae (NVTA) has contracted with Cigna (CI), Aetna (AET) and United Healthcare (UNH) over the past nine months to expand to 175M lives by year-end and following what may be some "short-term issues" he sees "exciting visibility" to an accelerating revenue outlook for the second half of 2017. Myers increased his price target on Invitae to $16 from $11 citing its substantial improvement in reimbursement and keeps a Buy rating on the shares.
05/08/17
05/08/17
NO CHANGE

Invitae reports Q1 EPS (64c), consensus (66c)
Reports Q1 revenue $10.3M, consensus $10.9M.
LH LabCorp
$159.97

-0.1 (-0.06%)

07/13/17
FBCO
07/13/17
NO CHANGE
Target $169
FBCO
Outperform
LabCorp price target raised to $169 from $146 at Credit Suisse
Credit Suisse analyst Erin Wilson Wright raised her price target for LabCorp to $169 from $146 on valuation. The analyst reiterates an Outperform rating on the shares.
07/25/17
PIPR
07/25/17
NO CHANGE
Target $107
PIPR
Neutral
Quest Diagnostics price target raised to $107 from $93 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target for Quest Diagnostics to $107 following the company's Q2 results. While Quest's fundamentals "are as strong as they have been in years," there is risk of longer-term multiple convergence with peer LabCorp (LH), Quirk tells investors in a research note. He keeps a Neutral rating on the shares.
07/27/17
CHLM
07/27/17
NO CHANGE
Target $179
CHLM
Buy
LabCorp price target raised to $179 from $157 at Craig-Hallum
Craig-Hallum analyst Kevin Ellich raised his price target for LabCorp to $179 from $157 following quarterly results to reflect the strength in the Diagnostics business. The analyst reiterates a Buy rating on the shares.
07/27/17
RHCO
07/27/17
NO CHANGE
RHCO
LabCorp reported 'strong' Q2 results, says SunTrust
SunTrust analyst David McDonald believes that LabCorp reported "strong" Q2 results that included "impressive lab volumes, strong pricing and solid free cash flow." The analyst raised his price target on the shares to $190 from $185 and keeps a Buy rating on the stock.
DGX Quest Diagnostics
$109.36

-0.15 (-0.14%)

07/25/17
BOFA
07/25/17
UPGRADE
BOFA
Buy
Quest Diagnostics upgraded to Buy from Neutral at BofA/Merrill
07/25/17
BOFA
07/25/17
UPGRADE
Target $118
BOFA
Buy
Quest Diagnostics upgraded on view FY18 consensus too low at BofA/Merrill
As previously reported, BofA/Merrill Lynch analyst Steven Valiquette upgraded Quest Diagnostics to Buy from Neutral as he believes that consensus estimates for 2018 seem too low given Quest's current momentum and the company's increased FY17 sales and EPS guidance. Valiquette raised his 2018 EPS estimate to $6.08, which he noted is "well above" the current consensus view of $5.91, adding that a delay in PAMA reimbursement changes could yield further EPS upside. The analyst increased his price target on Quest shares to $118 from $111.
07/26/17
ADAM
07/26/17
NO CHANGE
Target $118
ADAM
Buy
Quest Diagnostics weakness overdone, says Canaccord
Canaccord analyst Mark Massaro said Quest Diagnostics delivered solid Q2 results and raised its guidance. He believes Quest is well positioned to achieve growth from acquisitions, develop higher fee cash flow, and continue stock buybacks. Massaro said yesterday's modest pullback is overdone and he reiterated his Buy rating and $118 price target on Quest Diagnostics shares.
ILMN Illumina
$174.92

0.59 (0.34%)

04/26/17
LEER
04/26/17
NO CHANGE
Target $201
LEER
Outperform
Illumina price target raised to $201 from $195 at Leerink
Leerink analyst Puneet Souda raised his price target for Illumina to $201 from $195 after the company reported one of its most anticipated quarters with 135 NovaSeq instruments ordered in Q1 well above his 100 instrument estimate. The analyst reiterates an Outperform rating on the shares.
05/15/17
MSCO
05/15/17
NO CHANGE
Target $115
MSCO
Underweight
Illumina estimates reduced further at Morgan Stanley
Morgan Stanley analyst Steve Beuchaw reviewed underlying margin trends for Illumina and found a structural moderation due to a consumables deceleration, headcount growth, and a shift of volumes to more efficient platforms from legacy platforms. The analyst reduced earnings estimates by 6%/8%and revenues by 3%/4% in 2018/19, respectively and raised his price target to $115 from $108 and maintains an Underweight rating.
07/10/17
PIPR
07/10/17
NO CHANGE
Target $200
PIPR
Overweight
Piper checks on Illumina's NovaSeq suggest Q2 placement miss
Piper Jaffray analyst William Quirk says he found 41 NovaSeq installs during Q2, just above his 40 estimate but below the Street's 50 system target. The checks suggest limited NovaSeq placement upside in the quarter, Quirk tells investors in a research note. While a NovaSeq placement miss may move the stock lower, any shortfall could be made up with HiSeq X consumables and the array business, the analyst adds. He believes Illumina can meet revenue expectations for Q2. Quirk recommends using any earnings-related selloff in Illumina shares as a buying opportunity and keeps an Overweight rating on the name with a $200 price target.
07/28/17
DBAB
07/28/17
NO CHANGE
Target $175
DBAB
Hold
Deutsche uncovers 'surprise' Illumina order from PerkinElmer
Deutsche Bank analyst Dan Leonard says he learned at a recent genetics conference that PerkinElmer (PKI) placed a "surprise" order with Illumina (ILMN) for 10 NovaSeq's to support its planned offering in clinical nextgen sequencing. The analyst finds the size of the order, not PerkinElmer being a customer, as a surprise. Ten NovaSeq's is equivalent to the order placed by the Broad Institute, one of the largest genome centers in the world, the analyst points out. He believes demand for newborn sequencing is growing rapidly, "albeit off a small base." The order challenges, but does not change, the analyst's view that the NovaSeq product cycle is not as rapid as HiSeq's. Leonard keeps a Hold rating on Illumina shares with a $175 price target. The stock in early trading is up 44c to $174.77.
PACB Pacific Biosciences
$3.23

-0.02 (-0.62%)

12/15/16
CANT
12/15/16
NO CHANGE
Target $15
CANT
Overweight
Cantor says Roche deal termination significant negative for Pacific Biosciences
Cantor Fitzgerald analyst Bryan Brokmeier said Roche's (RHHBY) termination of its collaboration agreement with Pacific Biosciences is a "significant negative" for the latter, as he was forecasting Roche-generated revenues of $14.3M in 2017 and $27.5M in 2018. Pacific Bio should not lose all of that revenue, since it will now be able to sell into the clinical market or partner with another company, but that will require further investments, said Brokmeier, who has an Overweight rating and $15 price target on the stock.
12/15/16
PIPR
12/15/16
NO CHANGE
Target $6
PIPR
Neutral
Pacific Biosciences price target lowered to $6 from $10 at Piper Jaffray
Piper Jaffray analyst William Quirk lowered his price target for Pacific Biosciences (PACB) to $6 from $10 after Roche (RHHBY) terminated its Sequel system contract with the company. Pacific Biosciences believes Roche's decision stems from a change in the sequencing market dynamics, the analyst notes, adding that Roche said "somewhat vaguely" that Sequel can no longer meet a list of requirements the company established. Additionally, Quirk believes the mid-point of Pacific Biosciences' 2017 guidance may be difficult to reach, and reiterates a Neutral rating on the shares.
07/20/17
PIPR
07/20/17
NO CHANGE
Target $4.8
PIPR
Neutral
Pacific Biosciences checks imply potential Q2 downside, says Piper Jaffray
Piper Jaffray analyst William Quirk says his channel checks found 13 Sequel systems in the quarter, down sequentially from 21 found in Q1 and 13 in Q4. Pacific Biosciences typically places two times the channel check, which would imply 26 systems in the quarter, Quirk tells investors in a research note. He lowered his 33 estimate to 30 and sees risk to Q2 numbers. The analyst keeps a Neutral rating on Pacific Biosciences and dropped his price target for the shares to $4.80 from $5.10.
12/15/16
CANT
12/15/16
NO CHANGE
Target $8
CANT
Overweight
Pacific Biosciences a 'viable takeout target,' says Cantor
Cantor analyst Bryan Brokmeier says Pacific Biosciences' (PACB) shares are oversold after the company announced that Roche (RHHBY) has terminated their IVD-distribution agreement, whereby Roche had exclusive distribution rights of the Sequel into the clinical market. While the analyst acknowledges Roche's termination of the agreement is a clear long-term strategic negative, he says it is not nearly as much as the stock selloff is implying and notes that Pacific Biosciences is now positioned to sell into the clinical sequencing market directly or through other partners. Moreover, Brokmeier believes Pacific Biosciences is now "effectively a viable takeout target" for other companies, with Agilent (A), Bio-Techne (TECH), Illumina (ILMN), PerkinElmer (PKI), Thermo Fisher (TMO), and Roche among potential acquirers. He reiterated an Overweight rating on Pacific Biosciences' stock, but lowered his price target on the shares to $8 from $15.
QGEN QIAGEN
$33.16

-1.11 (-3.24%)

08/01/16
HSBC
08/01/16
UPGRADE
HSBC
Buy
QIAGEN upgraded to Buy from Hold at HSBC
HSBC analyst Keppeler upgraded QIAGEN to Buy and increased its price target to $27 from $20. The analyst is more constructive on improving trends in Academia/Pharma and expects topline growth to accelerate to 7% in 2017 from 1-4% in 2012-2015 from strong growth drivers that include QiaSymphony instrument and the NGS franchise.
11/03/16
BOFA
11/03/16
UPGRADE
Target $26
BOFA
Neutral
QIAGEN upgraded to Neutral from Underperform at BofA/Merrill
BofA/Merrill analyst Derik de Bruin upgraded QIAGEN to Neutral and raised its price target to $26 from $25 following the Q3 report and solid FY17 guidance. The company sees accelerating FY17 growth and the first double-digit increase since 2012 and said its Unperform thesis is played out.

TODAY'S FREE FLY STORIES

DE

Deere

$114.63

-9.355 (-7.55%)

10:30
08/18/17
08/18
10:30
08/18/17
10:30
Hot Stocks
Deere notes material cost increases impacting margins »

The company highlighted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

  • 22

    Nov

10:30
08/18/17
08/18
10:30
08/18/17
10:30
General news
U.S. consumer sentiment surged 4.2 points to 97.6 in the August »

U.S. consumer sentiment…

TXMD

TherapeuticsMD

$6.28

0.01 (0.16%)

10:29
08/18/17
08/18
10:29
08/18/17
10:29
Hot Stocks
Analysts upbeat on TherapeuticsMD after large NIH study »

Analysts this morning…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

APEI

American Public Education

$17.90

-0.05 (-0.28%)

10:28
08/18/17
08/18
10:28
08/18/17
10:28
Conference/Events
American Public Education management to meet with Barrington »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 24

    Aug

10:25
08/18/17
08/18
10:25
08/18/17
10:25
General news
Treasury Action: yields steadied above lows »

Treasury Action: yields…

10:25
08/18/17
08/18
10:25
08/18/17
10:25
Conference/Events
Cowen Washington strategist holds analyst/industry conference call »

Washington Research Group…

HPE

HP Enterprise

$17.11

-0.19 (-1.10%)

10:20
08/18/17
08/18
10:20
08/18/17
10:20
Options
Repeat option activity in Hewlett Packard Enterprises »

Repeat option activity in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

10:20
08/18/17
08/18
10:20
08/18/17
10:20
General news
The Michigan sentiment pop to 97.6 »

The Michigan sentiment…

MDU

MDU Resources

$25.82

0.01 (0.04%)

10:18
08/18/17
08/18
10:18
08/18/17
10:18
Syndicate
Breaking Syndicate news story on MDU Resources »

MDU Resources files mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

10:17
08/18/17
08/18
10:17
08/18/17
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

10:16
08/18/17
08/18
10:16
08/18/17
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOSL

Fossil

$7.77

-0.09 (-1.15%)

10:15
08/18/17
08/18
10:15
08/18/17
10:15
Options
Fossil put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
08/18/17
08/18
10:15
08/18/17
10:15
General news
FX Action: The dollar »

FX Action: The dollar…

AMTD

TD Ameritrade

$42.44

-0.93 (-2.14%)

10:13
08/18/17
08/18
10:13
08/18/17
10:13
Conference/Events
TD Ameritrade management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 24

    Aug

  • 06

    Sep

DE

Deere

$113.40

-10.58 (-8.53%)

10:12
08/18/17
08/18
10:12
08/18/17
10:12
Hot Stocks
Deere says long term global tail winds for agricultural economy in place »

Comments are from the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

  • 22

    Nov

CTL

CenturyLink

$19.13

-0.25 (-1.29%)

, LVLT

Level 3

$52.64

-0.35 (-0.66%)

10:12
08/18/17
08/18
10:12
08/18/17
10:12
Recommendations
CenturyLink, Level 3 analyst commentary  »

CenturyLink and Level 3…

CTL

CenturyLink

$19.13

-0.25 (-1.29%)

LVLT

Level 3

$52.64

-0.35 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$197.16

-0.832 (-0.42%)

10:11
08/18/17
08/18
10:11
08/18/17
10:11
Hot Stocks
General Dynamics awarded $115.3M contract modification by Navy »

General Dynamics Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

10:05
08/18/17
08/18
10:05
08/18/17
10:05
General news
FX Action: USD-CAD »

FX Action: USD-CAD fell…

IWM

iShares Trust Russell 2000 Index Fund

$134.44

-0.49 (-0.36%)

, RUT

Russell 2000 Index

10:02
08/18/17
08/18
10:02
08/18/17
10:02
Technical Analysis
Technical View: Russell 2000 Index nears key technical levels »

The Russell 2000 (RUT) is…

IWM

iShares Trust Russell 2000 Index Fund

$134.44

-0.49 (-0.36%)

RUT

Russell 2000 Index

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:01
08/18/17
08/18
10:01
08/18/17
10:01
General news
Consumer Sentiment Index data reported »

Consumer Sentiment Index…

QQQ

PowerShares QQQ Trust

$141.33

-2.95 (-2.04%)

10:00
08/18/17
08/18
10:00
08/18/17
10:00
Options
Defensive spread in PowerShares QQQ »

Defensive spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:00
08/18/17
08/18
10:00
08/18/17
10:00
General news
Breaking General news story  »

Dallas Federal Reserve…

IMUC

ImmunoCellular

$0.32

-0.0191 (-5.65%)

09:56
08/18/17
08/18
09:56
08/18/17
09:56
Conference/Events
ImmunoCellular to host conference call »

Business News Update…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

ROST

Ross Stores

$53.33

-1.04 (-1.91%)

, EL

Estee Lauder

$102.49

4.165 (4.24%)

09:55
08/18/17
08/18
09:55
08/18/17
09:55
Options
Early notable gainers among liquid option names on August 18th »

Notable gainers among…

ROST

Ross Stores

$53.33

-1.04 (-1.91%)

EL

Estee Lauder

$102.49

4.165 (4.24%)

NEM

Newmont Mining

$37.16

1.11 (3.08%)

AMAT

Applied Materials

$43.12

-1.34 (-3.01%)

XEC

Cimarex Energy

$96.89

0.59 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

  • 22

    Aug

  • 23

    Aug

DAL

Delta Air Lines

$47.54

0.01 (0.02%)

09:54
08/18/17
08/18
09:54
08/18/17
09:54
Upgrade
Delta Air Lines rating change  »

Follow-up: Delta Air…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.